Aug. 12 at 12:52 AM
$AVR Looks like a Slow start to this Trial. 40 Million cash burn?
Anteris recorded net operating cash outflows of US
$20.8 million for the 3 months to June 30, primarily related to clinical, regulatory and manufacturing requirements for PARADIGM.
Research and development expenses totalled US
$23.4 million, reflecting increased manufacturing and quality capabilities, process development and validation work, additional headcount and costs associated with patient enrolment and expansion of its field-based clinical team.
No Bueno!!!! Afraid we are taking a hit in the morning. Did not post Recruitment numbers???? Not Good cash management?
Where am I wrong.
